Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report

被引:0
作者
A. Karahasanovic
A.-L. Thorsteinsson
N. H. Bjarnason
P. Eiken
机构
[1] Nordsjaellands Hospital-Hillerød,Department of Cardiology, Nephrology and Endocrinology
[2] University of Copenhagen,Faculty of Health and Medical Sciences
[3] Copenhagen University Hospital,Department Respiratory Medicine
[4] Copenhagen University Hospital,Department Lung Transplantation
来源
Osteoporosis International | 2016年 / 27卷
关键词
Bisphosphonates; Cystic fibrosis; Leukopenia; Lung transplant; Osteoporosis; Zoledronic acid;
D O I
暂无
中图分类号
学科分类号
摘要
Cystic fibrosis (CF) is a serious autosomal recessive genetic disorder associated with chronic lung disease, malabsorption, malnutrition, pancreatic insufficiency and premature respiratory failure. Recent advances in medical science and technology have increased the lifespan of patients with CF, albeit with long-term consequences of the disease, such as osteoporosis, becoming of increasing significance. The medical treatment of osteoporosis in patients with CF or after organ transplantation is still being explored, and no clear guidelines regarding the best choice of bisphosphonate exist. We report a case of a young woman with CF, lung transplantation and low bone mass developing long-term leukopenia after treatment with zoledronic acid. The leukopenia, with a strong affection of the neutrocytes, lasted for 4 months and the condition only went into remission after granulocyte-colony stimulating factor (G-CSF) treatment. It is important to be aware of symptomatic leukopenia in immunosuppressive patients after treatment with zoledronic acid.
引用
收藏
页码:2621 / 2625
页数:4
相关论文
共 150 条
[1]  
Conwell LS(2014)Bisphosphonates for osteoporosis in people with cystic fibrosis Cochrane Database Syst Rev 3 CD002010-552
[2]  
Chang AB(2010)A roadmap to the brittle bones of cystic fibrosis J Osteoporos 2011 926045-193
[3]  
Gore AP(2013)Cystic fibrosis-related bone disease: insights into a growing problem Curr Opin Endocrinol Diabetes Obes 20 547-846
[4]  
Kwon SH(1998)Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis Ann Intern Med 128 186-254
[5]  
Stenbit AE(2009)Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF) Clin Endocrinol (Oxf) 70 838-944
[6]  
Stalvey MS(2012)The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 27 243-1263
[7]  
Clines GA(2015)The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 30 934-946
[8]  
Aris RM(2009)Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253-1769
[9]  
Renner JB(2000)Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation Am J Respir Crit Care Med 162 941-248
[10]  
Winders AD(2012)Sumatriptan (oral route of administration) for acute migraine attacks in adults Cochrane Database Syst Rev 2 CD008615-1136